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PCLINICAL RESEARCH Clinical Trial
The Final 10-Year Follow-Up
Results From the BARI Randomized Trial
The BARI Investigators*
Objectives We sought to compare 10-year clinical outcomes in the BARI (Bypass Angioplasty Revascularization Investiga-
tion) trial patients who were randomly assigned to percutaneous transluminal coronary balloon angioplasty
(PTCA) versus coronary artery bypass grafting (CABG).
Background Angioplasty and bypass surgery have been compared in numerous studies, but long-term clinical outcomes are
limited.
Methods Symptomatic patients with multivessel coronary artery disease (n  1,829) were randomly assigned to initial
treatment with PTCA or CABG and followed up for an average of 10.4 years. Analyses were conducted on an
intention-to-treat basis.
Results The 10-year survival was 71.0% for PTCA and 73.5% for CABG (p  0.18). At 10 years, the PTCA group had sub-
stantially higher subsequent revascularization rates than the CABG group (76.8% vs. 20.3%, p  0.001), but
angina rates for the 2 groups were similar. In the subgroup of patients with no treated diabetes, survival rates were
nearly identical by randomization (PTCA 77.0% vs. CABG 77.3%, p 0.59). In the subgroup with treated diabetes, the
CABG assigned group had higher survival than the PTCA assigned group (PTCA 45.5% vs. CABG 57.8%, p 0.025).
Conclusions There was no significant long-term disadvantage regarding mortality or myocardial infarction associated with
an initial strategy of PTCA compared with CABG. Among patients with treated diabetes, CABG conferred long-
term survival benefit, whereas the 2 initial strategies were equivalent regarding survival for patients without
diabetes. (J Am Coll Cardiol 2007;49:1600–6) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.048M
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fihe BARI (Bypass Angioplasty Revascularization Inves-
igation) randomized trial was designed to test whether
ercutaneous transluminal coronary balloon angioplasty
PTCA) compromised 5-year survival compared with
oronary artery bypass grafting (CABG) in patients with
ultivessel coronary artery disease (CAD). After 5 years
f follow-up, overall survival was similar for the 2
evascularization strategies (1); however, after 7 years of
ollow-up, CABG survival was statistically superior (2).
An unexpected finding of the BARI trial was that among
atients without treated diabetes, survival rates for the
TCA and CABG randomized groups were almost iden-
ical throughout the 7 years of follow-up, whereas among
atients with treated diabetes, the CABG group had sig-
ificantly better survival. The survival difference was attrib-
table to reduced cardiac mortality (3).
This report describes the final 10-year results from the
ARI randomized trial for the entire study group as well as
or subgroups defined by treated diabetes status.
Please see the Appendix for a full list of the BARI Investigators. This study was
upported by the following National Heart, Lung, and Blood Institute grants:
L38493, HL38504, HL38509, HL38512, HL38514-6, HL38518, HL38524-5,
L38529, HL38532, HL38556, HL38610, HL38642, and HL42145.i
Manuscript received August 11, 2006; revised manuscript received November 20,
006, accepted November 21, 2006.ethods
he BARI trial enrolled patients with angiographically
ocumented multivessel CAD and severe angina or objective
vidence of ischemia requiring revascularization, as described
reviously (1,2). Between 1988 and 1991, BARI randomized
,829 patients at 18 North American sites to receive initial
evascularization with either CABG or PTCA.
The vital status of each patient was ascertained on March
1, 2000; patients who had not completed 10 years of
ollow-up by that date were followed up until they reached
heir 10-year visit. The BARI study ceased following up
atients in 2002.
The primary end point was all-cause mortality, and
econdary end points included death of cardiac cause, the
omposite end point of death or Q-wave myocardial infarc-
ion (MI), the composite end point of death of cardiac cause
r any MI (Q-wave or non–Q-wave), subsequent revascu-
arization procedures, and anginal status. All MI events
ere classified by the BARI central laboratory (St. Louis
niversity) based on serial electrocardiographic analysis
egardless of symptoms (4). The cause of death was classi-
ed by an independent review committee.
A priori subgroups specified by the BARI protocolncluded anginal status, number of diseased vessels, proxi-
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April 17, 2007:1600–6 BARI Trial 10-Year Follow-Up Resultsal left anterior descending coronary artery disease, left
entricular function, and lesion complexity. The BARI
entral radiographic laboratory (Stanford University) inter-
reted baseline coronary angiograms (5). Based on a request
rom the study Data and Safety Monitoring Board in 1992,
atients were classified by treated diabetes status defined as
reatment with either oral hypoglycemic medication or
nsulin at study entry.
tatistical methods. Kaplan-Meier estimates and log
ank tests were used to compare death, cardiac events,
nd subsequent revascularization rates according to the
ntention-to-treat principle. The mean restricted life
xpectancy was estimated by the area under the survival
urve between 0 and 10 years. The significance of
tatistical interactions between randomized treatment
nd subgroup variables were assessed with Cox regres-
ion. Generalized estimation equations were used to
nalyze presence of angina over time, and Nelson-Aalen
ethods were used to estimate the number of subsequent
ARI Randomized Trial Baseline Characteristics by Assigned Treat
Table 1 BARI Randomized Trial Baseline Characteristics by As
Baseline Characteristics
All Patients
PTCA, %
(n  915)
CABG, %
(n  914) p Value
Demographic variables
Age 65 yrs 39 39 0.95
Female 27 26 0.64
Race 0.071
White 91 89
Black 5 7
Other race 4 3
History of smoking 72 69 0.48
Body mass index 30 kg/m2 28 30 0.25
Clinical history and status
History of myocardial infarction 54 55 0.62
History of congestive heart failure 9 9 0.83
History of hypertension 49 49 0.94
History of peripheral vascular disease 17 16 0.69
History of renal dysfunction 3 2 0.28
Treated diabetes 19 20 0.67
Insulin use 9 9 0.56
Angina 0.26
Stable class 1 or 2 15 15
Stable class 3 or 4 18 15
Unstable 68 70
Angina duration 1 yr 44 43 0.71
ECG characteristics
Any major ECG abnormality 43 42 0.74
Q waves 18 17 0.64
ST-segment elevation 5 4 0.41
ST-segment depression 6 6 0.91
Angiographic profile
Triple-vessel disease 41 41 0.99
Significant proximal LAD lesions 36 37 0.45
Class C lesions 38 41 0.26
Normal LV function 78 80 0.36ABG  coronary artery bypass graft; ECG  electrocardiogram; LAD  left anterior descending coronarrocedures. A value of p  0.05
as considered statistically sig-
ificant except for the treat-
ent comparisons within iden-
ified subgroups, in which p 
.01 was used to control for
ultiple comparisons.
esults
aseline characteristics of CABG
nd PTCA groups were similar
Table 1). The average follow-up was 10.4 years.
reedom from mortality and MI. At 10 years, mortality
nd MI event rates were not statistically different between
andomized treatment groups (Table 2, Figs. 1 and 2). The
ean restricted life expectancy after study enrollment was
.86 years for CABG-assigned patients and 8.63 years for
TCA-assigned patients.
and by Treated Diabetes Status
d Treatment and by Treated Diabetes Status
Patients Without Treated Diabetes Patients With Treated Diabetes
PTCA, %
n  742)
CABG, %
(n  734) p Value
PTCA, %
(n  173)
CABG, %
(n  180) p Value
38 37 0.75 41 44 0.45
23 22 0.702 44 42 0.67
0.026 0.31
94 90 80 85
4 7 10 9
2 3 10 6
74 70 0.22 62 67 0.34
24 26 0.55 43 49 0.25
54 54 0.95 54 60 0.22
6 6 0.81 20 19 0.85
45 45 0.78 65 66 0.79
16 15 0.54 23 24 0.86
2 1 0.15 6 6 0.92
0 0 100 100 0.78
0 0 45 47 0.69
0.51 0.45
15 15 13 13
17 15 21 16
68 70 66 71
44 44 0.98 47 42 0.36
42 41 0.78 49 47 0.802
17 17 0.86 21 18 0.47
5 4 0.47 4 3 0.72
5 6 0.78 8 7 0.76
41 40 0.67 44 48 0.44
36 36 0.93 34 42 0.13
38 41 0.26 40 41 0.78
80 82 0.29 69 69 0.92
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
MI  myocardial infarction
PTCA  percutaneous
transluminal coronary
balloon angioplastyment
signe
(y artery; LV  left ventricular; PTCA  percutaneous transluminal coronary balloon angioplasty.
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BARI Trial 10-Year Follow-Up Results April 17, 2007:1600–6Based on 10-year survival, there were no statistically
ignificant interactions between treatment and the subgroup
ariables analyzed (Fig. 3). Clinical outcomes were influ-
nced by treated diabetes status (Table 2, Fig. 4). Among
atients without treated diabetes, survival was comparable
or the randomized treatment groups throughout the 10
ears of follow-up. In the treated diabetes subgroup, pa-
ients assigned to CABG had significantly higher cardiac
urvival (p  0.01) and trends for better survival and greater
reedom from cardiac death or any MI (p 0.05); note that
he interaction between diabetes and treatment for freedom
rom cardiac death was significant (p  0.032). The mean
estricted life expectancy was 9.05 years for CABG-assigned
Figure 1 Overall Survival and Survival
Free of Q-Wave MI by Randomized Treatment
The blue solid lines indicate coronary artery bypass grafting (CABG), and percu-
taneous transluminal coronary balloon angioplasty (PTCA) by red dashed lines.
MI  myocardial infarction.
Figure 2 Freedom From Cardiac Death and Freedom From
Cardiac Death or Any MI by Randomized Treatment
The blue solid lines indicate CABG, and PTCA
by red dashed lines. Abbreviations as in Figure 1.T S S C C
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April 17, 2007:1600–6 BARI Trial 10-Year Follow-Up Resultsatients and 9.02 years for PTCA-assigned patients without
reated diabetes and 8.07 years for CABG-assigned patients
nd 6.93 years for PTCA-assigned patients with treated
iabetes.
Among patients with treated diabetes who received their
ssigned revascularization procedure, CABG patients re-
eiving at least 1 arterial graft (n  145) had 64.3% 10-year
urvival, compared with 39.4% in CABG patients receiving
nly vein grafts (n 33) and 45.5% in PTCA patients (n
3). Among patients without treated diabetes, there was no
ifference in 10-year survival between CABG patients with
n arterial graft (n  602, 75.3%) and those with only vein
rafts (n  134, 77.8%).
epeat revascularization. A significantly smaller propor-
ion of patients assigned to CABG received subsequent
evascularization (Table 3), and they had substantially fewer
evascularization procedures over the 10 years of follow-up
Fig. 5).
Figure 3 10-Year Survival Rates for Patients According to Subg
Ninety-nine percent confidence intervals of the absolute treatment difference betw
between treatment effect and subgroup is based on proportional hazards models.
sification of angina; CHF  congestive heart failure; ECG  electrocardiogram; LAD
infarction; PTCA  percutaneous transluminal coronary balloon angioplasty; PVD ngina. At 10 years, the prevalence of angina was similar
n the randomized treatment groups (Fig. 6). At 6
onths, angina was less frequent in CABG patients, but
he odds of having angina increased 8% per year for
ABG patients (p  0.001) and decreased 6% per year
or PTCA patients (p  0.001). Among surviving pa-
ients without diabetes, 10-year angina rates were 15.0%
or each treatment group, and among those with diabetes,
ates were 25.7% in the PTCA group and 23.1% in the
ABG group.
edications. A majority of patients received beta-
lockers, calcium antagonists, or long-acting nitrates (75%
TCA and 66% CABG at 8 years) and antiplatelet therapy,
lmost entirely aspirin (84% PTCA and 86% CABG at 8
ears). Rates of lipid-lowering therapy increased steadily
rom 29% PTCA and 21% CABG at 1 year to 65% PTCA
nd 63% CABG by 10 years.
s Based on Characteristics at Study Entry
-year survival rates are shown for each subgroup. The test of the interaction
 coronary artery bypass grafting; CCS  Canadian Cardiovascular Society clas-
ft anterior descending coronary artery; LV  left ventricular; MI  myocardial
heral vascular disease.roup
een 10
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BARI Trial 10-Year Follow-Up Results April 17, 2007:1600–6iscussion
he long-term follow-up of this large cohort of selected
atients with multivessel CAD randomized to receive either
alloon angioplasty or coronary bypass surgery shows similar
ates of survival and freedom from MI over 10 years. The
nitial cardiac revascularization procedures in BARI were
erformed between 1988 and 1991, before the introduction
f coronary stents and other technical refinements in angio-
lasty and surgery. Although some might argue that these
rocedural refinements make the results of the BARI trial
bsolete, we believe that our observations with respect to
eath and MI remain applicable to contemporary practice.
verviews of the randomized trials of bare metal stents (6,7)
nd drug-eluting stents (8,9) show that these devices have
o significant advantage regarding mortality or MI com-
ared with balloon angioplasty despite striking reductions in
ates of restenosis and repeat revascularization procedures.
urthermore, observational studies of patients undergoing
ngioplasty indicate that restenosis does not confer a worse
rognosis concerning survival (10).
Figure 4 Overall Survival by Randomized
Treatment Stratified by Diabetes Status
Patients who were being treated for diabetes at baseline are shown with heavy
lines, and all other patients are shown with light lines. The blue solid lines
indicate CABG, and the red dashed lines indicate PTCA. D  treated diabetes;
ND  no treated diabetes; other abbreviations as in Figure 1.
stimated Cumulative Rates of Subsequent Revascularizationrocedures* at 10 Y ars by Assigned Tr a m nt and by Treated D
Table 3 Estimated Cumulative Rates of Subsequent RevasculaProcedures* at 10 Years by Assigned Treatment and b
All Patients
PTCA (n  915) CABG (n  914)
No subsequent revascularization 33.2 79.7
No subsequent revascularization or
at most 1 subsequent PTCA†
43.4 89.8
Two or more subsequent PTCAs 27.2 6.8
Subsequent CABG 41.2 3.7
The percent of patients with subsequent procedures, subsequent CABG, or subsequent PTCA are
ubsequent PTCA procedure and no subsequent CABG).
Abbreviations as in Table 1.A comprehensive review of trials and registries comparing
ercutaneous coronary intervention with CABG is pre-
ented elsewhere (11). The BARI trial results are consistent
ith those of recent clinical trials such as ARTS (Arterial
evascularization Therapies Study) (12), which reported
omparable 5-year mortality for coronary bare-metal stent-
ng and CABG (8.0% stents vs. 7.6% CABG), but more
ubsequent revascularization (30.3% vs. 8.8%) and more
ngina (21.2% vs. 15.5%) in the stenting group. Meta-
nalyses (13) and registries (14) based on larger and more
iverse populations have shown small but statistically sig-
ificant survival advantages with CABG at 3 to 5 years. In
he New York cardiac registry, 37,212 multivessel CAD
atients undergoing CABG had better risk-adjusted sur-
ival than 22,102 undergoing stenting (14). Given the
bserved 10-year mortality rate in BARI, more than 7,200
atients would be required to have sufficient power to detect
3% absolute difference in mortality, thus reflecting the
hallenge of conducting clinical trials.
In patients with type 2 diabetes, CABG conferred a
onsistent, clinically relevant, absolute survival benefit over
alloon angioplasty that diminished somewhat over ex-
ended follow-up because patients in both groups had
es Status
on
ated Diabetes Status
atients Without Treated Diabetes Patients With Treated Diabetes
A (n  742) CABG (n  734) PTCA (n  173) CABG (n  180)
35.6 79.3 20.3 81.7
46.7 90.0 25.8 88.8
24.3 6.6 45.4 7.9
38.3 3.6 57.7 4.1
on Kaplan-Meier estimates at 10 years. †At most 1 subsequent PTCA procedure (i.e., no second
Figure 5 Cumulative Number of Subsequent Revascularization
Procedures per 100 Patients by Randomization
The blue solid lines indicate CABG, and the
red dashed lines indicate PTCA. Abbreviations as in Figure 1.iabet
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April 17, 2007:1600–6 BARI Trial 10-Year Follow-Up Resultsigher event rates. Five-year mortality results from ARTS
diabetes: 13.4% stents vs. 8.3% CABG, relative risk 
.61, p  0.27; no diabetes: 6.8% stents vs. 7.5% CABG,
elative risk  0.91, p  0.71) (15) support the finding that
ABG may have particular advantages for patients with
iabetes. It remains to be seen whether advances in percu-
aneous procedures and medical management over the past
ecade will make contemporary angioplasty a reasonable
ption in this cohort.
The steady incidence of cardiac events over the 10 years
f follow-up in both treatment groups emphasizes that
oronary revascularization does not reverse the underlying
athophysiology of coronary disease. Underuse of evidence-
ased medical therapies is unfortunately common among
atients with coronary disease. Clinical outcomes for all
atients may be improved further by providing long-term
ggressive medical management after revascularization.
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